Abstract：
Autologous dendritic cells (DCs) loaded with tumor-associated antigens (TAAs) are a promising immunological tool for cancer therapy. These stimulate the antitumor response and immunological memory generation. Nevertheless, many patients remain refractory to DC approaches. Antigen (Ag) delivery to DCs is relevant to vaccine success, and antigen peptides, tumor-associated proteins, tumor cells, autologous tumor lysates, and tumor-derived mRNA have been tested as Ag sources. Recently, DCs loaded with allogeneic tumor cell lysates were used to induce a potent immunological response. This strategy provides a reproducible pool of almost all potential Ags suitable for patient use, independent of MHC haplotypes or autologous tumor tissue availability. However, optimizing autologous tumor cell lysate preparation is crucial to enhancing efficacy. This review considers the role of cancer cell-derived lysates as a relevant source of antigens and as an activating factor for ex vivo therapeutic DCs capable of responding to neoplastic cells. These promising therapies are associated with the prolonged survival of advanced cancer patients.
摘要：
负载有肿瘤相关抗原（TAA）的自体树突状细胞（DC）是用于癌症治疗的有希望的免疫工具。这些刺激抗肿瘤反应和免疫记忆的产生。然而，许多患者仍然难以接受DC治疗。抗原（Ag）递送到DCs与疫苗成功有关，和抗原肽，肿瘤相关蛋白，肿瘤细胞,自体肿瘤裂解物，和肿瘤来源的mRNA已被测试为Ag来源。最近,负载有同种异体肿瘤细胞裂解物的DC用于诱导有效的免疫应答。这种策略提供了一个可重现的几乎所有适用于患者使用的潜在Ags库。独立于MHC单倍型或自体肿瘤组织可用性。然而,优化自体肿瘤细胞裂解液的制备对提高疗效至关重要。这篇综述认为癌细胞来源的裂解物作为抗原的相关来源和能够响应肿瘤细胞的离体治疗性DC的激活因子的作用。这些有希望的疗法与晚期癌症患者的生存期延长有关。
